Christopher H Moy

Title: Christopher H Moy: Innovator in Cancer Treatment

Introduction

Christopher H Moy is a notable inventor based in Schwenksville, PA (US). He has made significant contributions to the field of cancer treatment through his innovative research and patents. With a total of 2 patents, Moy's work focuses on identifying patients who are likely to respond to specific cancer therapies.

Latest Patents

Moy's latest patents include methods for using biomarkers to identify cancer patients who will be responsive to treatment with a PRMT5 inhibitor. The first patent describes methods that involve evaluating a biological sample from the patient for the presence of a spliceosome mutation or alteration. The presence of this alteration indicates a higher likelihood for the patient to respond positively to treatment with the PRMT5 inhibitor compared to those without the mutation or alteration.

Career Highlights

Christopher H Moy is currently employed at Janssen Pharmaceutica NV, where he continues to advance his research in cancer therapies. His work has the potential to significantly impact patient outcomes by personalizing treatment options based on genetic markers.

Collaborations

Moy collaborates with esteemed colleagues such as Dirk Brehmer and Lijs Beke, contributing to a dynamic research environment focused on innovative cancer treatments.

Conclusion

Christopher H Moy's contributions to cancer treatment through his patents and research exemplify the importance of innovation in medicine. His work not only enhances our understanding of cancer responsiveness but also paves the way for more effective treatment strategies.